XPO1 and breast cancer: Although CRM1 knockdown or inhibiting CRM1 using Leptomycin B did not affect Cdh1 expression (Supplementary Fig. 7d, e), a significant enrichment of Cdh1 in the nuclear fraction was observed in CRM1-deficient breast cancer cells (Fig. 7f and Supplementary Fig. 7f).